Summary
Pharma Legrand is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €272,538 and a net result of €162,257. Equity is growing by about 26% per year across the filed financial years. Its solvency ranks better than 15% of 6,640 sector peers (NACE 64, financial year 2025). The company has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals.
Articles of association
- Other provisionsOther rules from the articles that fall under none of the themes above.
- 1 more provision in the deed, see the deed of 04-12-2023
Read from the deeds: 1 provision, deed of 04-12-2023